All In Biotech

Drug Trial Radar · NCT00505778

A Comparison of Once a Day Dose Compared to 2 Doses/Day

A Multi-center, Investigator-blinded, Randomized, 12-month, Parallel-group, Non-inferiority Study to Compare the Efficacy of 1.6 to 2.4 g Asacol® Therapy QD Versus Divided Dose (BID) in the Maintenance of Remission of Ulcerative Colitis

Last checked: Nov 19, 2026Latest source record: Apr 22, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,027 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,027

Actual

Start

Jul 2007

Primary completion

Jul 2009

Study completion Jul 2009

Sponsor

Lead sponsor
Warner ChilcottIndustry
Sponsor type
Industry
First posted
Jul 23, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy in maintaining remission of ulcerative colitis between a once daily (QD) Asacol regimen and a divided, twice daily (BID) Asacol dosing regimen.

Conditions

  • Ulcerative Colitis

Interventions

  • Mesalamine Once-DailyDrug

    Mesalamine tablets, 1.6-2.4 g/day taken orally once a day for 52 weeks

  • Mesalamine Twice-DailyDrug

    Mesalamine tablets, 1.6-2.4 g/day, taken twice daily for 52 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients Remaining in Remission at Month 6, ITT Population, Determined by the Simple Clinical Colitis Activity Index (SCCAI)Time frame: 6 months

Locations

245 sites in 3 countries. Site status is shown where the registry gives one.

  • Research Facility

    Athens, Alabama

  • Research Facility

    Birmingham, Alabama

  • Research Facility

    Birmingham, Alabama

  • Research Facility

    Dothan, Alabama

  • Research Facility

    Phoenix, Arizona

  • Research Facility

    Scottsdale, Arizona

  • Research Facility

    Tucson, Arizona

  • Research Facility

    Tuscon, Arizona

  • Research Facility

    Little Rock, Arkansas

  • Research Facility

    Lowell, Arkansas

  • Research Facility

    Anaheim, California

  • Research Facility

    Beverly Hills, California

  • Research Facility

    Chico, California

  • Research Facility

    Encinitas, California

  • Research Facility

    Folsom, California

  • Research Facility

    La Mesa, California

  • Research Facility

    Lancaster, California

  • Research Facility

    Long Beach, California

  • Research Facility

    Los Angeles, California

  • Research Facility

    Los Angeles, California

  • Research Facility

    Madera, California

  • Research Facility

    Merced, California

  • Research Facility

    Mission Hills, California

  • Research Facility

    Monterey, California

  • Research Facility

    Murrieta, California

  • Research Facility

    Oakland, California

  • Research Facility

    Orange, California

  • Research Facility

    Palm Springs, California

  • Research Facility

    San Carlos, California

  • Research Facility

    San Diego, California

  • Research Facility

    San Diego, California

  • Research Facility

    San Diego, California

  • Research Facility

    San Francisco, California

  • Research Facility

    San Francisco, California

  • Research Facility

    Torrance, California

  • Research Facility

    Torrance, California

  • Research Facility

    Upland, California

  • Research Facility

    Englewood, Colorado

  • Research Facility

    Golden, Colorado

  • Research Facility

    Lafayette, Colorado

Showing 40 of 245 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.